Xenon Pharmaceuticals
XENE
39 hedge funds and large institutions have $31.3M invested in Xenon Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 5 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 38 → 39 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.9% less ownership
Funds ownership: 56.17% → 55.27% (-0.9%)
22% less capital invested
Capital invested by funds: $40.3M → $31.3M (-$8.97M)
Top Buyers
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.22M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$489K |
| 3 |
Morgan Stanley
New York
|
+$317K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$186K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$149K |
Top Sellers
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.44M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.36M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$600K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$391K |
| 5 |
Renaissance Technologies
New York
|
-$339K |
XENE Hedge Fund Activity: Q2 2017 in Review
39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2017, worth a combined $31.3M — down 22% from $40.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 7 trimmed.
The largest buyer was BVF Inc, adding an estimated $2.22M. The largest seller was Opaleye Management, exiting entirely with an estimated $1.44M sold.
- 39 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2017, up from 38 in Q1 2017.
- Funds reported $31.3M of Xenon Pharmaceuticals stock for Q2 2017, down 22% quarter-over-quarter.
- 6 funds opened new Xenon Pharmaceuticals positions in Q2 2017 and 5 closed out, a net change of +1 holder.
- The largest Xenon Pharmaceuticals buyer in Q2 2017 was BVF Inc, an estimated $2.22M added.
- The largest Xenon Pharmaceuticals seller in Q2 2017 was Opaleye Management, an estimated $1.44M sold.
Based on aggregated 13F filings for Q2 2017.